Rapid Micro Biosystems Inc (RPID)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$1.31-5.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Rapid Micro aims for $37M to $41M revenue in 2026. It targets a 20% gross margin. The company is improving after past earnings misses. New tech could boost growth.
The company is still losing money. It missed earnings many times. Growth may slow and margins may stay weak. Debt and leadership changes add risk.
The price is about 47% below our fair value near $3.38. Analysts expect 23% revenue growth. The market prices in a cautious recovery but risks remain.
Breaks if: Earnings misses continue or worsen over next 4 quarters
The company needs to address recurring earnings misses to improve financial performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. RPID is currently in a watch state due to recent earnings misses and high near-term risk, but it operates in a sector with favorable tailwinds.
The market appears to price RPID as a cheaper option compared to its peers, with a notable expectations gap. However, the valuation is justified given the company's current loss-making status and the recent financial performance.
Management is on track to achieve revenue and gross margin guidance, although placements show mixed results. The company's fundamentals may continue to improve, but the elevated risk of an earnings miss remains a concern.
Key factors include the potential for management to maintain or cut guidance, the performance of sector bellwethers, and broader economic conditions affecting employment. These scenarios could significantly impact RPID's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about the company's financial performance. The overall market has also shown a risk-off sentiment recently.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Gross margin falls below 15% in FY26
Sustain gross margin percentage guidance of approximately 20% for full year 2026 with expected mid-20% margins in second half.
Stated as a priority in 2 of last 2 quarters. Management reaffirmed full year 2026 gross margin guidance of approximately 20%. Actual gross margin improved from 4.6% in 2026-Q1 to 15.0% in 2026-Q2, showing meaningful progress toward the mid-20% second half target. The trajectory is delivering positive margin expansion.
“Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with second half 2026 margins in the mid-20% range”
“Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with Q4 2026 exit rate in mid-20% range”
Breaks if: Revenue falls below $37M in FY26
Continue executing to meet full year 2026 total revenue guidance range of $37.0 million to $41.0 million including 30 to 38 Growth Direct system placements.
Stated as a priority in 2 of last 2 quarters. Management reaffirmed full year 2026 total revenue guidance range of $37.0 million to $41.0 million including 30 to 38 Growth Direct system placements in both 2026-Q1 and 2026-Q2. Revenue grew from $8.0 million in 2026-Q1 to $8.1 million in 2026-Q2, showing consistent execution but still below the annual midpoint pace. The trajectory is delivering steady progress toward the guidance.
“Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million including 30 to 38 Growth Direct system placements”
“Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements”
In the next 1 to 3 years, RPID's performance will depend on its ability to navigate risks while capitalizing on sector momentum. Not investment advice.